Sanofi India refutes a news article published in the Economic Times on 15 April 2025, concerning the speculated sale or licensing of its insulin brand, Lantus.
The company clarifies that the information in the article is 'completely unfounded and incorrect'.
Sanofi India explicitly states that it has no plans to divest, sell, or license its brand Lantus.
The company reiterates its commitment to high corporate governance standards and timely disclosure of all material information to the stock exchanges as per regulatory requirements.